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INTRODUCTION
Prostate cancer is themost common cancer and the
second leading cause of death inmen inNorth America
(1). In Japan, age-standardizedmortality has increased
by 150%over the25yearsup to1997(2).Themajorcause
of death from this disease is metastasis of hormone-
refractory cancer cells. Themetastases are commonly
found in lymph nodes or bones (1, 3), and the specific
organ microenvironment can influence the biological
behavior of metastatic cells, including their response
to systemic therapy (4). Stephen Paget proposed that
some tissuesmayprovide abetter environment thanother
tissues for the growth of certain tumor cells (the seed)
are compatible with a particular organ tissue (the soil).
Metastasis only resulted when the seed and soil were
compatible (5). A prime example of this principle is the
contribution of angiogenesis to thegrowthandmetastasis
of cancer. The growth and spreadof prostate cancer are
dependent on the formation of adequate vasculature, i.e.,
angiogenesis regulated by angiogenic factors (6 -8).
TUMOR-ASSOCIATED ANGIOGENESIS
Angiogenesis consists of multiple, sequential, and
interdependent steps dependent on the local balanceof
positive and negative regulatory factors.Themajor pro-
angiogenic factors include vascular endothelial growth
factor/vascular permeability factor (VEGF/VPF), inter-
leukin-8(IL-8), fibroblastgrowth factor 2 (FGF2), epider-
mal growth factor (EGF) and platelet-derived growth
factor (PDGF), and the major antiangiogenic factors
include interferon (IFN), endostatin, angiostatin, and
thrombospondin (8 -14).
Tumor-associated angiogenesis refers to the growth
of new vessels toward and within the tumor. Tumors
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can not grow no longer than2-4mmindiameteruntil they
are vascularized (9, 15).Compellingdata implicate tumor-
associated angiogenesis as a central pathologic step in
the process of tumor growth, invasion, andmetastasis.
Several studies have revealed that increasing intra-
tumoral microvessel density, amajorof tumor-associated
angiogenesis, correlateswithgreatertumoraggressiveness,
such asahigher frequencyofmetastasesand/ordecreased
survival inprostate cancerandothersolidtumors(15-17).
PROANGIOGENIC MOLECULES
1) Vascular endothelial growth factor (VEGF)
VEGF is one of the most potent facilitators of angio-
genesis with affect on endothelial cell proliferation,
motility, and vascular permeability. VEGF binds with
high-affinity to the tyrosine kinase receptors Flt-1
(VEGFR-1) and Flk-1/KDR (VEGFR-2) expressed by
endothelial cells (18-22). VEGF expression has been
demonstrated in prostate cancer specimens (23) and in
LNCaP, PC3, and DU145prostate cancer cell lines
(24 -26). Kuniyasu et al. evaluated the expression level
of VEGF/VPF in archival prostatectomy specimens
from prostate cancer patients using a rapid colorimetric
in situ hybridization technique. The relationshipbetween
advancing pathological stage and expression of VEGF/
VPF genewas highly significant. Increased expression
of VEGF/VPFwas associatedwith theGleasonscore of
the tumors (27).Monoclonal antibodies that neutralize
VEGF inhibit both the growth andmetastatic spreadof
DU145 prostate cancer xenografts in severe combined
immune-deficientmice anddecrease thegrowthofLNCaP
tumors in nude mice, suggesting that VEGF is a critical
factor for the progression of prostate cancer (28, 29).
Additionally, expressionofVEGFR-1 andR-2 inprostate
cancer, prostatic intraepithelial neoplasia, and the basal
cells of normal glands, has been reported (23, 30). In
comparison withnormalglands, theexpressionof VEGFR-
1 and R-2 increases in prostatic intraepithelial neoplasia
and well to moderately differentiated prostate cancer.
These observations suggest that VEGF plays a role on
tumor cell activation (autocrine), in addition to paracrine
actions whereby it regulates endothelial cell functions
and subsequent neovascular development (23).
Recently, vascular endothelial growth factorC (VEGF-C)
which belongs to the platelet-derived growth factor
(PDGF)/VEGF family of growth factors was identified
as a ligand for the endothelial-specific receptor tyrosine
kinases VEGFR-3andVEGFR-2.TheexpressionofVEGFR-
3 was found to be highly restricted to the lymphatic
endothelial cells (31). VEGF-C expression in prostate
cancer cells is implicated in the lymph nodemetastasis
(32).
2) Interleukin-8(IL-8)
IL-8,whichbelongs to the superfamily ofCXCchemoki-
nes, has a wide range of proinflammmatory effects and
is produced by various cells, including lymphocytes,
monocytes, endothelial cells, fibroblasts, hepatocyte,
keratinocyte, and various tumor cells includingprostate
cancer cells (33, 34). It hasbeenshown thatIL-8enhances
production andsecretionofcollagenasetypeIVby tumor
cells, suggesting that it can modulate invasiveness,
and/or extracellular matrix remodeling in the tumor
environment. Ascell proliferation, angiogenesis,migration,
and invasion are important component of themetastatic
process, IL-8 expression by tumor cells can influence
their metastatic capabilities (35). Indeed, the expression
of IL-8 has been shown to correlate with angiogenesis
and the metastatic potential of human prostate cancer
cells (36-38).When lowandhigh IL-8-producingclones
isolated from the heterogeneous PC3 human prostate
cancer cell line were injected into the prostate of nude
Table１．Tumorigenic potential of PC-３cells with low or high expression of IL-８．
Number of Cells Injected１ PC-３IL-８low PC-３IL-８high
Incidence２ Tumor Weight Median (range) Incidence Tumor Weight Median (range)
１．２５×１０４
２．５×１０４
５×１０４
１×１０５
２×１０５
５×１０５
０／５
０／５
１／５
１／５
４／４
５／５
０
０
１２０
１００
１８０（１４０‐２００）
２３０（１９０‐２７０）
０／５
０／５
４／４
５／５
５／５
５／５
０
０
１７０（１１０‐１８０）
２２０（１００‐２４０）
６７０（４２０‐７８０）
８６０（５６０‐１０４０）
１Nude mice (n＝５）were given prostate injections of the incidental number of PC-３IL-８low or high cells. The mice were killed
５weeks later at which point the prostate and tumors were removed and weighed (tumor weight is in milligrams).
２Number of positive mice/number of mice injected.
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mice, PC3 cells expressing high levelsof IL-8werehighly
tumorigenic, producing rapidly growingprostate tumors.
On the other hand, low IL-8-expressingPC-3 cellswere
less tumorigenic, producing slower growing tumors
(Table 1). Additionally, prostate tumorsproducedbyhigh
IL-8 -expressing PC-3 cells showed higher vascularity
with significantly higher incidence of metastasis than
the tumors produced by low IL-8-expressing PC-3 cells
(38).
The pleiotropic transcription factor NF-κB regulates
the expression of multiple genes including IL-8and
matrix metalloproteinase (MMP)-9in several types
of cells (39-42), and is constitutively activated in prostate
cancer cells(43). Blockade of NF-κB activity in human
prostate cancer cells inhibits in vitro and in vivo expres-
sion of VEGF, IL-8 and MMP-9, and hence decreases
neoplastic angiogenesis (44).
3) Fibroblast growth factor 2(FGF 2)
FGF2 (i.e. bFGF) is synthesized mainly by stromal
fibroblasts in prostate.When prostate cancer converts
to an invasive phenotype, the cancer cells respond to
FGF 2 through high-affinity FGFR 2Ⅲc receptor. Then,
the cancer cells synthesize their ownFGF2 topropagate
their own growth. In addition, secretedFGF2actson the
endothelial cells to promote tumor angiogenesis (45).
Several studies have shown that themetastatic potential
of prostate cancer cells directly correlated with the
gene expression level ofFGF2 (46, 47).Metastatic variant
of human prostate cancer cell line expresses higher
FGF 2 mRNA than parental cell line (47).
4) Epidermal growth factor (EGF)
The interaction of EGFwith its receptor EGF-R has
been shown to play an important role in neoplastic
angiogenesis (48-50). The expression of VEGF,major
proangiogenic factor, is strongly induced by EGF and
transforming growth factor-α (51, 52). The expression
of EGF andEGF-R is observed in both benignprostatic
hyperplasia andprostate cancer (53, 54). Several studies
have shown that the metastatic potential of prostate
cancer cells directly correlated with the expression
level of angiogenesis -and metastasis-related genes
including EGFR (19, 55).
5) Platelet-derived growth factor (PDGF)
PDGF is a dimer that consist of AA, BB and AB
proteins, and a ligand of PDGF receptor (PDGF-R), a
member of a family of protein tyrosine kinases, encoded
by two genes (PDGF-Rα and PDGF-Rβ)(56). PDGFand
PDGF-R are co-expressed inmanyhumancancers includ-
ing prostate cancer (57). The bindingofPDGFtoPDGF-
R can stimulate cell division (58-60), cellmigration (61),
and angiogenesis (62).
ANTIANGIOGENIC MOLECULES
1) Interferon (IFN)
IFNs aremultifunctional regulatory cytokines involved
in control of cell function and replication. IFN-α and
IFN-β directly inhibit the proliferation of tumor cells of
different histological origins (63-66). IFN-α and IFN-β
can also down-regulate the expression of proangiogenic
molecules, such as FGF2 (67-69) and IL-8(70, 71). The
combined treatment with pegylated IFN-αanddocetaxel
inhibits neoplastic angiogenesis by inducingadecrease
in the local production of proangiogenic molecules by
human prostate cancer cells in nude mice, resulting in
increased apoptosis of tumor-associated endothelial
cells (72).
2) Endostatin
Endostatin is a 20kDaC-terminal fragmentof collagen
XVIII. Endostatin specifically inhibits endothelial pro-
liferation andpotently inhibits angiogenesis(73).Endosta-
tin treatmentdelays theonset of spontaneousmammary
tumorigenesis in female transgenicmice, andprolonged
survival timeofmale transgenicmice thatdevelop prostate
adenocarcinomas (74).
INHIBITION OF TUMOR-ASSOCIATED ANGIO-
GENESIS BY MOLECULAR TARGETING
AGENTS
Therapeutic approaches targeting the receptors of
proangiogenic molecules and their signal transduction
cascade may result in small avascular tumorsmaintained
in a dormant state or, perhaps in combinationwith cyto-
toxic therapies, theymay potentiate shrinkageof tumors.
PDGF binding causes PDGF-R activation, which
involves dimerization andautophosphorylation (i.e. activa-
tion) of specific tyrosines in the cytoplasmic domain of
PDGF-R. Activation of PDGF-R has been shown to
inhibit some apoptotic pathways in normal cells and
in tumor cells (75, 76).Wedeterminedwhetherblockade
of the PDGF-R signaling pathway by oral administration
of STI571(Gleevec, Novartis Pharmaceuticals), PDGF-R
tyrosine kinase inhibitor, inhibits the growth of PC-3
MM 2human prostate cancer cells in the bone of nude
mice. PC-3 MM2 induced lytic lesions in the bone and
expanded into the surrounding muscle. Tumor cells
adjacent to the bone expressed high levels of VEGF,
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IL - 8, FGF2, PDGFB, PDGF-R β, and activated PDGF-
R β, compared with the tumor cells growing in the
surrounding muscle (Fig.1). Treatment with STI571
or STI571 plus paclitaxel inhibited tumor growth and
angiogenesis, and it was more effective to the tumor
cells adjacent to the bone (77).
Agents targeting epidermal growth factor-receptor
(EGF-R) and its signal transduction cascade include 1)
monoclonal antibodies, directedagainst the extracellular
binding domain of the receptor, or binding to theHER
2 receptor ; and 2) low-molecular-weight inhibitors
of the EGF-R tyrosine kinase.
Cetuximab(C225, ImCloneSystems, Inc.) is a chimeric
monoclonal antibodywithspecificity fortheexternal ligand-
binding domain of EGF-R. Both dihydrotestosterone and
EGF can stimulate proliferation of androgen-responsive
prostate cancer cell lines,MDAPCa2aandMDAPca2b,
and thisproliferation is associatedwith stimulationofcyclin-
dependent kinase (CDK)-2 activity and downregulation
of the CDK inhibitor gene p27Kip1. Dual blockade of the
EGF-R familywithC225andof androgen-receptor function
resulted in significant growth inhibition (78). Treatment
with C225 with or without paclitaxel inhibits growth,
metastasis, and angiogenesis of PC-3M-LN4 prostate
cancer cells implanted orthotopically in athymic nude
mice(79).
ZD1839 (AstraZeneca), a low-molecular-weight anilino-
quinazoline is a potent and specific inhibitor of EGFR
tyrosine kinase activity. EGF-induced neovascularization
of mice cornea is inhibited by ZD1839 treatment (80).
Administration of ZD1839 and more so ZD1839 plus
cytotoxic agents inhibit the growth of a wide range of
human tumors grown as xenografts innudemice, includ-
ing prostate tumors (81). PKI 166 (Novartis Pharma-
ceuticals) is also a selective inhibitor of EGFR tyrosine
kinase activity.TreatmentwithPKI166 inhibits thegrowth
and angiogenesis of PC-3MM2human prostate cancer
cells implanted in the bone of nude mice (82).
DC 101(ImClone Systems, Inc.) is a neutralizing
monoclonal antibody that binds to themurine VEGFR-
2/flk-1 receptor with high affinity and blocks ligand-
induced receptor activation.Tumorigenicity,metastasis,
and neovascularization in orthotopic prostate cancer
xenografts in nude mice are reduced by a treatment
with DC 101(83).
CONCLUDING REMARKS
Prostate cancer is themost common cancer inNorth
America. The prostate cancer death rate is rapidly
increasing in Japan. The major cause of death from
prostate cancer ismetastasesthatareresistant to therapy.
In prostate cancer, same as other cancers, tumor-
associated angiogenesis is a crucial step in the proc-
ess of tumor growth, invasion, and metastasis, and
depends on the local balance of proangiogenic and
antiangiogenic factors. Therefore therapeutic agents
and strategies are being devised either to interrupt or
inhibit one ormore of the pathogenic steps involved in
the process of tumor neovascularization or to directly
Fig.1. Immunohistochemical analysis of the different expression
of vascular endothelial growth factor (VEGF), interleukin 8(IL-
8), fibroblast growth factor 2 (FGF2), platelet-derived growth factor
B (PDGF B), PDGF receptor β (PDGF-R β), and activated PDGF-
R β by PC-3 MM2 cells growing in the hind leg bones (left column)
and surrounding muscles (right column) of control nude mice.
The expression of VEGF, IL-8, FGF2, PDGF B, PDGF-R β (brown)
and activated PDGF-R β (red), was higher in bone lesions than
muscle lesions.
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target and destroy the tumorvasculature.Antiangiogenic
therapy may provide anadditional novel prostate cancer
treatment suitable for combinationwithstandardtherapies.
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